Todd Girolamo - Caladrius Biosciences General Counsel
| CLBSDelisted Stock | USD 0.43 0.39 895.37% |
Executive
Mr. Todd Girolamo Esq. is was promoted as General Counsel of the Company. Todd Girolamo joined Caladrius in 2011. He is a seasoned attorney specializing in healthrelated products and businesses. As a member of the Caladrius senior management team Mr. Girolamo was responsible for managing all legal aspects of the Companys research and development pipeline from preclinical research to multinational pivotal clinical trials including academic and corporate collaborations. He was responsible for the Companys licensing activities the strategy maintenance and prosecution of the Companys extensive global patent estate and the management of all litigation involving the Company and its subsidiaries. Mr. Girolamo began his legal career as an associate at Cahill Gordon Reindel and concluded his tenure in private practice at Reid Priest where he gained expertise as a general commercial litigator practicing in the areas of intellectual property securities law employment law and bankruptcy. In addition to over a decade of experience as both corporate counsel and private practitioner Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer Co. CIBC World Markets Leerink Swann Company and Summer Street Research Partners since 2015.
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 908 842-0100 |
| Web | www.caladrius.com |
Caladrius Biosciences Management Efficiency
The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (23.84) %, meaning that it generated substantial loss on money invested by shareholders. Caladrius Biosciences' management efficiency ratios could be used to measure how well Caladrius Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 626 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Caladrius Biosciences has a current ratio of 31.73, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Caladrius Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Caladrius Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Caladrius Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Caladrius to invest in growth at high rates of return. When we think about Caladrius Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| T Frickle | Glacier Bancorp | N/A | |
| Nicholas Campbell | Siriuspoint | 55 | |
| Leslie Sutton | Discover Financial Services | N/A | |
| Angela CPA | Glacier Bancorp | N/A | |
| Bill Chippendale | Discover Financial Services | N/A | |
| Karen Caddick | Siriuspoint | 55 | |
| David Langston | Glacier Bancorp | N/A | |
| Adrian Holt | Eastman Chemical | 55 | |
| Walter III | The Mosaic | 60 | |
| Paul Peterson | Glacier Bancorp | 74 | |
| Jason Strle | Discover Financial Services | 47 | |
| Christopher Lewis | The Mosaic | 62 | |
| Tracey Gibbons | Siriuspoint | N/A | |
| Anthony LeHan | Siriuspoint | 63 | |
| Justin Brenden | Siriuspoint | 40 | |
| Linda Lin | Siriuspoint | N/A | |
| Mark MacMillan | Glacier Bancorp | N/A | |
| Paul CFA | The Mosaic | N/A | |
| Stephen Yendall | Siriuspoint | 49 | |
| Shifra Kolsky | Discover Financial Services | N/A | |
| Travis Smith | Eastman Chemical | N/A | |
Management Performance
| Return On Equity | -23.84 | |||
| Return On Asset | -16.73 |
Caladrius Biosciences Leadership Team
Elected by the shareholders, the Caladrius Biosciences' board of directors comprises two types of representatives: Caladrius Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caladrius. The board's role is to monitor Caladrius Biosciences' management team and ensure that shareholders' interests are well served. Caladrius Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caladrius Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Mazzo, CEO, Director | ||
| Catherine Vaczy, Vice President | ||
| Robert Preti, CTO, Sr. VP of Manufacturing and Technical Operations and Director | ||
| Eric Wei, Director | ||
| Richard Berman, Independent Director | ||
| Steven Myers, Independent Director | ||
| Cynthia Schwalm, Director | ||
| Todd Girolamo, General Counsel | ||
| Gregory Brown, Director | ||
| Steven Klosk, Independent Director | ||
| Douglas Losordo, Chief Medical Officer | ||
| Martyn Greenacre, Independent Director | ||
| Joseph Talamo, CFO and Sr. VP | ||
| Andrew Pecora, Chief Visionary Officer, Director | ||
| Peter Traber, Independent Director | ||
| Drew Bernstein, Independent Director |
Caladrius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caladrius Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.84 | |||
| Return On Asset | -16.73 | |||
| Current Valuation | (57.88 M) | |||
| Shares Outstanding | 59.78 M | |||
| Shares Owned By Insiders | 2.74 % | |||
| Shares Owned By Institutions | 18.51 % | |||
| Number Of Shares Shorted | 543.94 K | |||
| Price To Earning | (0.28) X | |||
| Price To Book | 0.25 X | |||
| Price To Sales | 1.00 X |
Pair Trading with Caladrius Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Caladrius Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Caladrius Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Caladrius Stock
| 0.56 | MRNA | Moderna Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Caladrius Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Caladrius Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Caladrius Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Caladrius Biosciences to buy it.
The correlation of Caladrius Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Caladrius Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Caladrius Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Caladrius Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Caladrius Biosciences information on this page should be used as a complementary analysis to other Caladrius Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Caladrius Stock
If you are still planning to invest in Caladrius Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Caladrius Biosciences' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |